

**Trustee**



## **Pratik C. Shah**

Pratik C. Shah is President and CEO of Auspex Pharmaceuticals, a clinical stage biopharmaceutical company focused on developing innovative therapeutics for the treatment of orphan diseases. Auspex Pharmaceuticals is owned by Israeli drug maker Teva Pharmaceuticals. He is also a Partner at Thomas, McNerney and Partners, a health care venture firm that invests in life science and medical technology companies at all stages of development.

Dr. Shah has more than 15 years of entrepreneurial and leadership experience in the biopharma industry. In 2001, he co-founded the biotech startup Kalypsys, a spinoff from the Genomics Institute of the Novartis Research Foundation that focused on high-end robotics to expedite drug research. Prior to Kalypsys, Mr. Shah was at McKinsey & Company, where he focused on biotechnology and venture capital, including projects such as the spin-off of a new venture from a leading biotechnology company, development of corporate strategies for informatics and biopharmaceutical companies, and due diligence for mergers and acquisitions and venture investing. Prior to joining McKinsey, Mr. Shah was a Co-Founder and Vice President of Operations at NephRx Corporation. He was also involved in helping Arch Venture Partners with their biotechnology seed investments.

He serves as a Director at Cebix Incorporated; SG Biofuels, Inc.; and CNS Therapeutics, Inc. He also served as a Director of Ocera Therapeutics, Inc. from 2005 to 2014. He has authored original research and review papers in the field of molecular biology. He holds a Ph.D. in Biochemistry and Molecular Biology, an M.B.A. from the University of Chicago, and a B.S. in Biological Sciences from the University of California at Irvine.